| Jul 22 |
Addex’s Partner Discontinues ADX71149 development in Epilepsy
|
| Jul 18 |
J&J ends work on Addex epilepsy drug candidate ADX71149: report
|
| Jul 15 |
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
|
| Jul 12 |
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
|
| Jul 1 |
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
| Jun 6 |
Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript
|
| Jun 6 |
Addex Therapeutics GAAP EPS of -CHF 0.01, revenue of CHF 0.24M
|
| Jun 6 |
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
|
| Jun 5 |
Addex Convenes Annual General Meeting 2024
|
| May 31 |
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
|
